Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia
- Status
- TERMINATED
- Phase
- PHASE2
Clinical Trials Related to Waldenstrom Macroglobulinemia
Related studies linked through entity extraction aliases.
Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Study of VTD in Waldenstrom's Macroglobulinemia
- Status
- UNKNOWN
- Phase
- PHASE2
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
- Status
- COMPLETED
- Phase
- PHASE1
Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE2
Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)
- Status
- COMPLETED
- Phase
- PHASE1
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
- Status
- COMPLETED
- Phase
- PHASE2
Study of Lenalidomide in Relapse/Refractory Waldenstrom Macroglobulinemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
B-Cell Hematologic Malignancy Vaccination Registry
- Status
- WITHDRAWN
- Phase
- N/A
Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Status
- RECRUITING
- Phase
- N/A
Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1